Phase 4 N=20 Randomized Basic Science

Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

Aging · Diabetes Mellitus, Type 2 · PreDiabetes · Overweight and Obesity

Bottom Line

View on ClinicalTrials.gov: NCT05786521 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2025

Primary outcome: Primary: Lean Body Mass Change — -1730.6; -421 g

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Semaglutide Injectable Product (Drug); Lifestyle Counseling (Behavioral)
Age: Older Adult · 65+ yrs
Sex: All
Sponsor: The University of Texas Health Science Center at San Antonio
Primary completion: May 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Lean Body Mass Change	-1730.6; -421	—

Summary

Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.

Eligibility Criteria

Inclusion Criteria

Older than 65
Have prediabetes or diabetes
BMI ≥ 27.0 kg/m2
Living independently (not in assisted living or nursing home)

Exclusion Criteria

Have heart disease
Have liver disease
Smoke

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05786521). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.